Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower ...

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

Viatris Inc. VTRS delivered third-quarter 2024 adjusted earnings of 75 cents per share, which beat the Zacks Consensus ...

Viatris is poised for appreciation with new product launches and a stronger balance sheet. Read why VTRS stock is a buy due ...

Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Good morning, everyone, and welcome to the Viatris Q3 2024 Earnings Call. All participants will be in a listen-only mode. [Operator ...

Patent disputes following copycat activity are ... $500 million in sales from its knockoff of Pfizer's cholesterol pill Lipitor during its first six months on the market. The competitive nature ...

health plans and others have asked a U.S. appeals court to revive their lawsuits accusing pharmaceutical company Ranbaxy of conspiring with Pfizer to delay the release of a generic version of the ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

Get detailed information on Atorvastatin, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a ...

CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a ...

Odds ratio was 2.59 (without statins: 0.62; with statins: 1.48; p = 0.002). Patients treated with atorvastatin and simvastatin were compared (the number of patients taking other statins was too ...